Investor Presentaiton slide image

Investor Presentaiton

For personal use only Building a high-value diagnostics portfolio "Breakthrough Therapy" designation, clinical leadership opportunity • • • Biologics License Application (BLA) consultation process has commenced, Phase III study in final stages of enrolment TLX250-CDX is an investigational product being developed for the imaging of clear cell renal cell carcinoma (ccRCC) with PET/CT Current options for patients are limited, potential for clinical leadership with a non-invasive imaging modality for ccRCC Being studied as an imaging agent assessing ability to determine if "indeterminate renal masses" are malignant through improved, whole of body imaging May aid decision making and avoid unnecessary surgical intervention Opportunity to follow prostate cancer imaging, with a second high-value product for the genitourinary (GU) oncology field TELIX PHARMACEUTICALS An example of PET/CT imaging showing the uptake of 89Zr-girentuximab in a primary renal mass. The insert shows the identification of a metastatic lesion of the proximal radius, confirmed as ccRCC upon biopsy. 1 1. Hekman et al, European Urology. 2018. Telix Pharmaceuticals Limited (ASX: TLX) 40
View entire presentation